(Q34517173)

2 August 2017

1 reference

title

Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects (English)

1 reference

2 August 2017

Lazzaroni M

1

1 reference

2 August 2017

Bianchi Porro G

series ordinal

2

1 reference

2 August 2017

publication date

1 December 2001

1 reference

Digestive and Liver Disease

2 August 2017

published in

1 reference

2 August 2017

volume

33 Suppl 2

1 reference

2 August 2017

page(s)

S44-58

1 reference

Nonsteroidal anti-inflammatory drugs

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Guidelines for the medical management of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Guidelines for the medical management of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Protective effect of sucralfate against aspirin-induced damage to the human gastric mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Does sucralfate reduce acetylsalicylic-acid-induced gastric mucosal bleeding?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Sucralfate for prevention of naproxen-induced mucosal lesions in the proximal and distal gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Gastric adaptation occurs with aspirin administration in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Does sucralfate prevent short-term NSAID induced damage to the gastroduodenal mucosa?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Antacids and gastric mucosal protection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Alimentary tract and pancreas. Stimulation of mucosal prostaglandin synthesis in human stomach and duodenum by antacid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Are antacids cytoprotective?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Putative mechanisms of cytoprotective effect of certain antacids and sucralfate

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Intragastric pH in the gastroprotective and ulcer-healing activity of aluminum-containing antacids

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Acute damage of gastroduodenal mucosa by acetylsalicylic acid: no prolonged protection by antacids

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Role of H2-receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Cimetidine tablets or suspension for the prevention of gastrointestinal mucosal lesions caused by non-steroidal, anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Abolition by omeprazole of aspirin induced gastric mucosal injury in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Omeprazole ameliorates aspirin-induced gastroduodenal injury

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Effect of sucralfate and cimetidine on rheumatoid patients with active gastroduodenal lesions who are taking nonsteroidal anti-inflammatory drugs. A pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Healing of peptic ulcers during continuing anti-inflammatory drug therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

The influence of cimetidine on peptic ulcer in patients with arthritis taking anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Aspirin concurrently administered with ranitidine does not delay healing of duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori infection in elderly people: correlation between histology and serology

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study☆, ☆☆

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2801%2980158-4

7 January 2021

10.1016/S1590-8658(01)80158-4

Identifiers

DOI

1 reference

2 August 2017

1 reference